Cancer technique takes on autoimmune diseases: CAR t cells target lupus, scleroderma, and Sjogren's
NCT ID NCT06947460
First seen Mar 08, 2026 · Last updated May 20, 2026 · Updated 7 times
Summary
This study tests a new treatment using a patient's own immune cells, modified to attack harmful cells in three severe autoimmune diseases: lupus kidney disease, scleroderma, and Sjogren's syndrome with lung complications. About 45 adults will receive a single infusion of CD19-BCMA CAR T cells. The main goal is to check safety within the first month, but researchers will also watch for disease improvement up to 2 years. This is not a cure; patients may still need ongoing care.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for REFRACTORY LUPUS NEPHRITIS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
北京高博医院
RECRUITINGBeijing, China,Beijing, 102200, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.